Genentech's tocilizumab shortage due to Covid-19 now hits CAR-T recipients, with FDA offering alternatives to help

Soon after San Francisco-based Genentech won an EUA for tocilizumab as a treatment for hospitalized Covid patients last summer, the company announced a shortage of the drug while pointing to the emergence of the Delta variant and the slowing of vaccination rates across the US.